Skip to main content

Table 1 (abstract P87). Stratification of efficacy parameters by CAN dose category and weight (N=54)#

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Baseline

6 months

12 months

18 months

% of patients on low/standard/high dose CAN, number# of patients analysed (N)

4/77/19, N=47

31/41/28, N=32

42/27/31, N=26

36/36/28, N=14

 

PGA absent/mild-moderate/severe

Physician Global Assessment (PGA),

%# of patients

lower than SD* CAN

54/23/15

80/10/0

78/22/0

80/20/0

SD* CAN

42/50/0

88/12/0

50/33/0

50/25/0

higher than SD* CAN

20/60/20

33/67/0

0/67/0

0/100/0

 

VAS 0–10, (min; max)

Patients' assessment of current disease activity (median)

lower than SD* CAN

1 (0; 9)

1 (0; 7)

1 (0; 4)

2 (0; 3)

SD* CAN

2 (0; 10)

3 (0; 7)

3 (0; 10)

4 (0; 10)

higher than SD* CAN

4 (1; 5)

3 (0; 6)

3 (1; 5)

4 (1; 6)

  1. *Body weight >40kg: SD is 150 mg per 4 weeks; Body weight ≤40 kg: SD is 2mg/kg per 4 weeks #Numbers/percentage do not sum up to N=54/100%, due to unknown weight in a number of patients